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Kaposi’s sarcoma (KS)-associated herpesvirus (KSHV) open reading frame 50 (ORF50) encodes a viral
transcriptional activator, which binds to the KSHV promoter and stimulates the transcription of viral early
and late genes, thus activating the lytic cycle of KSHV. We report here that KSHV ORF50 binds to the cellular
proteins CREB-binding protein (CBP) and histone deacetylase (HDAC) and these binding events modulate
ORF50-activated viral transcription. Binding of ORF50 to CBP and HDAC activates and represses, respec-
tively, ORF50-mediated viral transcription. KSHV ORF50 was shown to bind to the C/H3 domain and the
C-terminal transcriptional activation domain of CBP, while CBP bound to the amino-terminal basic domain
and the carboxyl-terminal transactivation domain of ORF50. The LXXLL motif within the transcriptional
activation domain of ORF50 is reminiscent of the CBP-binding sequence found in nuclear receptor proteins.
The adenovirus E1A protein, which also binds to the C/H3 domain of CBP, repressed the transcriptional
activation activity of ORF50. The cellular protein c-Jun, which binds to the kinase-induced activation domain
of ORF50, stimulated ORF50-mediated viral transcription. The HDAC1-interacting domain of ORF50 was
shown to be a central proline-rich sequence. Our data provide a framework for delineating the regulatory
mechanisms used by KSHV to modulate its transcription and replication through interaction with both histone
acetyltransferases and HDACs.
The acetylation states of histones have been known to cor-
relate with transcriptional status. The level of histone acetyla-
tion is determined by histone acetyltransferase (HAT) and
histone deacetylase (HDAC) activities (14, 19, 32). The tran-
scriptional status of a gene may thus be determined in part by
an intrinsic balance of HAT and HDAC activities (14, 19, 32).
The best-characterized cellular proteins that are positive reg-
ulators of histone acetylation are the cyclic AMP (cAMP)-
responsive element binding protein (CREB)-binding protein
(CBP) and p300. p300 and CBP are transcriptional coactiva-
tors, and p300 was first identified as an adenovirus E1A-inter-
acting protein. p300 and CBP are highly homologous both
structurally and functionally (14), and both have intrinsic HAT
activities that contribute directly to the acetylation of histones
(5, 25).
Well-defined, highly conserved regions of these coactivators
interact with a large number of cellular proteins. Cellular tran-
scriptional regulatory proteins, cAMP-activated CREB, and
c-Jun bind to the kinase-induced activation (KIX) domain of
CBP and p300 and use CBP and p300 as coactivators for their
transcription (2, 10, 18, 20). Members of a class of cellular
transcription factors known as the nuclear receptors bind to
the N-terminal region of CBP (18). The cellular bZIP protein
c-Fos (4) and adenovirus E1A (1, 13, 23) bind to the C/H3
region of CBP. In addition to the transcription factors men-
tioned above, a group of proteins that participate in transcrip-
tional coactivation, such as the p300/CBP-associated factor
(P/CAF) and SRC-1, also form transcriptional coactivator
complexes with CBP and p300 (18, 35). The tumor suppressor
protein p53 binds to several conserved regions (C/H1, C/H3,
and KIX domains) of CBP (3, 15, 30). Interestingly, the pres-
ence of CBP and p300 is correlated with the differentiation and
proliferation states of cells, as these coactivators interact with
a number of cell cycle regulatory proteins.
HDACs, on the other hand, are known as repressors of
transcription. Deacetylation reverses the acetylation process
and causes the formation of tightly packaged nucleosomes,
which are inaccessible to transcription factors (34). Transform-
ing growth factor b receptor-activated Smad 2 and 4 signaling
proteins move into the nucleus and associate with CBP to
activate transcription, while activated Smads can also be in-
duced by tumor growth inhibitory factor to recruit the inhibi-
tory HDAC complex to the site of transcription (33). Spl,
another well-characterized cellular transcription factor, binds
to the CBP-p300 coactivator complex, and Sp1 activity is re-
pressed by direct interaction with HDAC1 (12). Similarly, cel-
lular transcription factor YY1 also binds to CBP and HDAC
and uses both HAT and HDAC activities to regulate transcrip-
tion (34). Several proteins from animal viruses use HDAC to
repress their own viral promoters and to modify host cell
growth. For example, the E7 oncoprotein from human papil-
lomavirus interacts with Mi2 and the HDAC complex to pro-
mote cell growth (8), and the Epstein-Barr virus (EBV) nu-
clear antigen 3C interacts with HDAC to repress transcription
of the latency-associated viral Cp promoter (26).
Kaposi’s sarcoma (KS)-associated herpesvirus (KSHV) has
been identified as an important pathogen in KS (6). In KSHV
infection, the viral DNA is found principally in B cells, and
KSHV is in fact associated with abnormal lymphoproliferation
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(9). In a KS tumor, KSHV DNA is found in spindle cells, and
viral lytic replication is important in KS tumor development
(7). The most important step in the KSHV life cycle may be the
switch from latency to lytic replication. Upon chemical induc-
tion, KSHV produces immediate-early viral transcripts. These
transcripts encode viral transcriptional activator proteins such
as open reading frames (ORFs) 50 and K8, which are necessary
to induce the lytic phase (36). ORF50 is a homolog of the EBV
immediate-early gene product Rta. It has been reported that
ORF50 could activate the lytic cycle of KSHV and is expressed
earlier than K8, a homolog of EBV Zta protein, which induces
the lytic cycle of EBV (22, 28). ORF50 is a viral transcriptional
activator, which activates the early and late genes in the KSHV
lytic cycle (21). We speculate that KSHV ORF50 uses CBP/
p300 as a coactivator for transcriptional activation.
Here, we show that CBP participates in transcriptional ac-
tivation by ORF50 and that CBP-binding proteins such as E1A
and c-Jun also influence the transcriptional activation activity
of ORF50. We also identified the CBP-binding domains in
ORF50, which include the N-terminal basic domain and the
conserved LXXLL motif of ORF50. In addition, we show that
HDAC suppressed ORF50 activity and directly binds to the
proline-rich sequences in the middle region of ORF50. Our
data suggest that both HAT and HDAC activities may play
important roles in controlling latent and lytic cycles of KSHV
by acting as sensors of the conditions for lytic replication in
infected cells.
MATERIALS AND METHODS
Plasmids. The expression plasmids containing hemagglutinin (HA)-tagged
CBP and HDAC1 are kind gifts from Didier Trouche. The vector containing
p300 was obtained from Steve Grossman. The c-Jun-containing vector was pro-
vided by Dennis J. McCance. The pFR-Luc reporter was obtained from Strat-
agene (San Diego, Calif.). pM and pVP16 used in the mammalian two-hybrid
assay were from Clontech (Palo Alto, Calif.). ORF50 and the ORF50 deletion
mutants were subcloned into the pcDNA3 (Invitrogen, Carlsbad, Calif.) (the
EcoRI and XhoI sites), pM (the EcoRI and XbaI sites), and pVP16 (the EcoRI
and XbaI sites) vectors using PCR. Flag/ORF50 was derived from pFLAG-
CMV-2. Green fluorescent protein (GFP) fusion vectors were constructed using
pEGFP-C1 (Clontech). The CBP fragments were introduced into pGEX4T-1
(Amersham Pharmacia Biotech, Uppsala, Sweden), and the GST fusion proteins
were expressed and purified according to the manufacturer’s instruction.
Transient-transfection assays. Transfection assays were performed in 293T
cells using the calcium phosphate method. In all assays, the luciferase activity
derived from the reporter plasmids was determined after normalizing to b-ga-
lactosidase activity from a cotransfected Rous sarcoma virus–b-galactosidase
(RSV-bgal) control plasmid. All experiments were performed in triplicate.
Equivalent expression of each plasmid was verified by Western blot assay (data
not shown). 293T cells were transfected with 1 mg of reporter plasmid, 20 ng of
RSV-bgal control plasmid, and the amounts of the expression plasmids indicated
in the figures. The total amount of each expression vector was kept constant by
adding empty cytomegalovirus expression plasmid. BJAB cells were transfected
by electroporation as described previously (21).
GST pull-down assays. All ORF50 and deletion mutants were in vitro tran-
scribed and translated using a T7-coupled transcription-translation system (Pro-
mega, Madison, WI). The labeled proteins were incubated with 1 mg of a
glutathione S-transferase (GST) fusion protein in binding buffer (20 mM HEPES
[pH 7.4], 100 mM NaCl, 0.5% NP-40 supplemented with protease inhibitors).
Glutathione beads were then added, and the reaction mixture was incubated at
4°C overnight. The beads were then washed four times with binding buffer,
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample
buffer was added, and the proteins were analyzed by SDS-PAGE and visualized
by autoradiography or phosphorimaging (BAS-1500, Fuji Film Co., Tokyo, Ja-
pan).
Coimmunoprecipitation assays. 293T cells were transfected with 7 mg of each
expression plasmid using the calcium phosphate method. The cells were har-
vested 48 h after transfection and lysed in the binding buffer (containing 1%
Triton X-100) used in the GST pull-down assays. The cell lysates were rotated in
the buffer for 1 h at 4°C before the cell debris was removed via centrifugation.
The appropriate lysates were immunoprecipitated with the addition of antibodies
to HA or Flag (Sigma, St. Louis, Mo.) and protein G resin (Santa Cruz Biotech-
nology, Santa Cruz, Calif.). The beads were washed four times, and the proteins
were analyzed by SDS-PAGE, transferred to a nitrocellulose membrane, and
visualized with ECL reagent according to the manufacturer’s instructions (Am-
ersham Pharmacia Biotech).
RT-PCR. BCBL-1 cells were transfected by electroporation. RNA was pre-
pared from the transfected cell lysates, and reverse transcription (RT)-PCR was
performed as described previously (27). The first PCR product (1 ml) was ob-
tained, and PCR (20 cycles) was performed again. The final PCR product was
analyzed by agarose gel electrophoresis and ethidium bromide staining.
Immunofluorescence. pGFP/ORF50 (1 mg) and expression vectors containing
HA-tagged CBP and HDAC were transfected into 293T cells (1 mg). Cells were
fixed and immunostained 48 h after transfection. HA-tagged CBP and HA-
tagged HDAC1 were detected using a rhodamine-conjugated secondary anti-
body.
RESULTS
CBP, p300, and HDAC1 modulate the transcriptional acti-
vation function of ORF50. To investigate whether KSHV
ORF50 interacts functionally with HATs and HDACs, we
fused ORF50 to the Gal4 DNA-binding domain (Gal4/
ORF50) and tested its ability to activate transcription of a
GAL4 reporter plasmid (pFR-Luc) in transfected 293T cells.
Transcriptional activation by Gal4/ORF50 was ;4,000 times
that of the Gal4 DNA-binding domain alone (Fig. 1A). We
then measured Gal4/ORF50 activity in the presence of CBP
and p300 to assess the effect of HAT activity on ORF50 func-
tion. We next tested whether HDAC activity could also mod-
ulate ORF50 activity. Cotransfection of an HDAC1 expression
vector resulted in the repression of ORF50 activity (Fig. 1A),
and this repression was relieved by cotransfection of the CBP.
In order to investigate the functional interactions among
CBP, p300, HDAC1, and ORF50, the effects of antisense CBP
DNA and an inhibitor of HDAC, trichostatin A (TSA), were
measured in our transfection assay. The cotransfection of an-
tisense CBP DNA reduced transcriptional activation by
ORF50 to 0.2-fold of the control value (Fig. 1B). Conversely,
increasing concentrations of TSA stimulated the activity of
ORF50 up to fourfold. These results confirm that HDAC1 and
CBP interact functionally with ORF50 in vivo to repress and
activate, respectively, its transcriptional activation activity. The
above experiments were repeated with the natural KSHV pro-
moter (Rp). ORF50 stimulated this transcription from the
natural promoter up to 18-fold. ORF50 activity was increased
by cotransfection of CBP or addition of TSA and decreased by
cotransfection of HDAC1 (Fig. 1B). Cotransfection of anti-
sense CBP DNA and HDAC1 expression vectors reduced tran-
scriptional activation by ORF50 to 0.1-fold in the B-cell lym-
phoma BJAB cell line (Fig. 1C). Conversely, increasing
concentrations of TSA stimulated the activity of ORF50 up to
fourfold in the BJAB cells. We also tested the effects of CBP
and HDAC1 on the ORF50-induced lytic phase of KSHV in
the BCBL-1 cell line, which carries a latent KSHV genome.
KSHV ORF29 (encodes a capsid protein) expression occurs
late in the lytic phase and is followed by viral DNA replication.
Therefore, in order to detect entry into the lytic phase, we
performed RT-PCR with oligonucleotides 29A and 29B, which
spanned both ends of ORF29A and ORF29B (27). An RT-
1910 GWACK ET AL. J. VIROL.
 o
n
 January 5, 2015 by ULSAN NATIO
NAL INS O
F SCIENCE & TECHNO
LO
G
Y(UNIST)
http://jvi.asm.org/
D
ow
nloaded from
 
FIG. 1. CBP, p300, and HDAC1 modulate the transcriptional activation function of ORF50. (A) 293T cells were transiently cotransfected with
a reporter gene construct (pFR-Luc, which contains Gal4 DNA-binding sites) and one or more of the following expression vectors: Gal4, a pM
vector containing a Gal4 DNA-binding domain alone (10 ng), Gla4/ORF50, a pM vector containing the Gal4-ORF50 fusion protein with the Gal4
DNA-binding domain fused to ORF50 (10 ng); CBP (amounts shown in the figure); p300 (amounts shown in the figure); and HDAC1 (amounts
shown in the figure). The effects of CBP, p300, and HDAC1 on the transcriptional activation function by ORF50 were determined by measuring
the luciferase activity of the reporter gene (pFR-Luc) in the transiently transfected 293T cells. The luciferase activity of Gal4 in the absence of the
other expression vectors is normalized to 1. (B) To confirm the results shown in panel A, antisense CBP DNA and the HDAC inhibitor TSA were
introduced into the 293T cells along with the transfected DNAs indicated (left panel). The effects of the two inhibitors were verified using the
pGL2-basic promoter gene under the control of the promoter region of KSHV ORF50 (nucleotides 70501 to 71595) (Rp) (right panel). The basal
luciferase activity of Rp in the absence of the other expression vectors is normalized to 1. (C) antisense CBP DNA, HDAC1, and the HDAC
inhibitor TSA were introduced into the B-cell lymphoma cell line BJAB along with the transfected DNAs indicated. (D) The RT-PCR product
(300 bp) of ORF29, the KSHV capsid protein, was analyzed with RNA prepared from KSHV-containing BCBL-1 cells transfected by electro-
poration with pcDNA3/ORF50 alone or with an HDAC1 expression vector or antisense CBP DNA. The RT-PCR product of the cellular
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene served as a loading control and was unchanged in all experiments.
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PCR product of ;300 bp was observed when ORF50 was
introduced into the BCBL-1 cells. Antisense CBP DNA and
HDAC1 reduced the amount of ORF29 RT-PCR product
produced in a dose-dependent manner (Fig. 1D). We conclude
that CBP and HDAC1 have stimulatory and inhibitory effects,
respectively, on the lytic cycle-inducing functions of ORF50.
In vivo and in vitro interaction of ORF50 with CBP. We next
sought to determine whether ORF50 interacts directly with
CBP and HDAC. To detect CBP-ORF50 interactions in vitro,
we performed GST pull-down assays using in vitro-translated
ORF50 and GST-CBP fusion proteins (made with various CBP
deletion mutants) (Fig. 2A). ORF50 bound with high affinity to
the CBP2 fragment (C/H3 region) and weakly to the CBP3
fragment (C-terminal transcriptional activation domain) (Fig.
2B). The CBP-ORF50 interaction was also observed in vivo
when plasmids expressing Flag-tagged ORF50 and HA-tagged
CBP were transfected into 293T cells. The cell extracts were
subjected to immunoprecipitation with anti-Flag antibodies
and Western blotting with anti-HA antibodies or anti-Flag
(Fig. 2C).
Modulation of the transcriptional activation function of
ORF50 by CBP-interacting proteins. Dozens of cellular tran-
scription factors bind to CBP (Fig. 2A). We thus selected
several CBP binding proteins and tested their effects on the
transcriptional activation activity of ORF50 in transiently
transfected 293T cells. The adenovirus E1A protein, which
binds to the C/H3 conserved region of CBP (amino acids 1680
to 1891) (1, 13, 23), repressed ORF50 activity in a dose-de-
pendent manner. ORF50 repression by E1A was greater when
a CBP expression vector was cotransfected into the 293T cells
(Fig. 3A). These results imply that E1A represses ORF50
transcriptional activation activity by interacting with CBP and
that ORF50 uses CBP as a transcriptional coactivator.
We next tested the effects of several cellular proteins that
associate with the KIX domain (amino acids 457 to 722) of
CBP. c-Jun protein stimulated ORF50 activity in a dose-de-
pendent manner (Fig. 3A), and the addition of CBP yielded an
incremental increase in ORF50 activity. We also used the
mammalian two-hybrid assay to perform a competition exper-
iment with E1A and c-Jun and measure their effects on inter-
action in vivo of ORF50 with CBP fragments 2 and 3 (CBP23;
amino acids 1680 to 2441) fused to the Gal4 DNA-binding
domain (Gal4/CBP23). ORF50 was fused to the transcriptional
activation domain of VP16 (VP16/ORF50), and a luciferase
gene fused to Gal4 DNA-binding sites served as the reporter.
The VP16/ORF50 fusion protein caused an increase in lucif-
erase production over that achieved with Gal4/CBP23 alone.
The E1A protein inhibited the VP16/ORF50-Gal4/CBP23 in-
teraction in a dose-dependent manner, while c-Jun had no
effect (Fig. 3B). These results imply that E1A competes with
ORF50 for binding to the same region of CBP.
CBP-interacting domains within ORF50. To determine the
CBP-binding domain of ORF50, we constructed various
ORF50 deletion mutants (Fig. 4A). The LXXLL motif was
found in the transcriptional activation domain of ORF50. This
motif constitutes a CBP-interacting motif in several proteins,
including SRC-1 and p/CIP (16, 24, 29, 31). We hypothesized
that the LXXLL motif of ORF50 constitutes a domain for
binding to CBP and constructed several deletion mutants that
did not contain this motif (N589, N449, N299, N246, C607-691,
and LXXAA) (Fig. 4A) for use in ORF50-CBP binding assays.
We first performed the mammalian two-hybrid assay using
vectors expressing the various ORF50 deletion mutants fused
to the VP16 transcriptional activation domain and CBP fused
to the Gal4 DNA-binding domain (Gal4/CBP). Gal4/CBP ac-
tivated transcription of Gal4-Luc more than did the Gal4
DNA-binding domain alone. This activity was stimulated a
further threefold in the presence of the ORF50-VP16 fusion
(Fig. 4B). The ORF50 mutants N626 and N599-VP16 dis-
played activity similar to that of wild-type ORF50-VP16, but
the ORF50 mutant N589-VP16 lost the ability to transactivate
the Gal4-Luc reporter gene. Unexpectedly, another CBP-in-
teracting domain was identified in the mammalian two-hybrid
assay. The ORF50 mutant C301-691 fusion protein, which has
FIG. 2. In vivo and in vitro interaction of ORF50 with CBP. (A)
The domains of CBP that interact with various cellular factors and the
GST-fused CBP fragments are indicated. CBP contains the KIX, HAT,
and zinc finger motifs and carboxyl-terminal transcriptional activation
domain (TAD). (B) The GST-fused CBP fragments were purified and
used in GST pull-down assays performed with glutathione-Sepharose
beads. ORF50 was translated in vitro and labeled with [35S]methi-
onine. (C) The coimmunoprecipitaion of in vivo-synthesized ORF50
and CBP was analyzed by Western blotting. 293T cells were trans-
fected with an HA-tagged CBP expression vector (pCMVCBP) and
either a blank (control) vector or an expression vector carrying Flag-
tagged ORF50 (Flag/ORF50). Proteins in the cell lysates were precip-
itated with anti-Flag antibody, subjected to SDS-PAGE, transferred to
a nitrocellulose membrane, and visualized with either anti-Flag (a-
Flag) or anti-HA (a-HA) antibodies.
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a deletion of 300 amino acids from the N terminus of
ORF50, lost most of its ability to activate transcription of
the reporter gene. We then repeated the mammalian two-
hybrid assay with Gal4/CBP23. As expected, the CBP23
fragment showed the same pattern as the wild-type CBP
(Fig. 4B). More C301-691-VP16 than of ORF50-VP16 was
expressed, as shown in Fig. 4C. The expressed amounts of
N589, N449, and N299-VP16 deletion mutants were at least
not smaller than the amount of ORF50-VP16, although
some variations were detected (lanes 1, 5, 6, and 7). Since
these deletion mutants did not activate the reporter activity
as did the wild-type ORF50, even though the deletion mu-
tants were expressed in greater amounts than the wild type,
we can conclude that the decreased interaction of C301-691,
N589, N449, and N299 with CBP was not due to lower
expression of the deletion mutants.
In order to determine ORF50 domain binding to CBP, we
performed the GST pull-down assay using a GST-CBP2 frag-
ment and in vitro-translated C301-691 and N299 (Fig. 4D).
Unexpectedly, both of these two domains interact with CBP in
the in vitro binding assay. To define the role of the LXXLL
motif in the interaction with CBP more clearly, we constructed
point-mutated proteins LXXAA and C301-691 (LXXAA).
C301-691 (LXXAA) lost its ability to bind to CBP (Fig. 4D).
This mutation reduced the transcriptional activity of Gal4
DNA-binding domain-fused ORF50 to 0.3-fold of the wild-
type level (Table 1). These facts imply that this LXXLL motif
should have a role as a CBP-interacting domain in vivo and in
vitro. From these experiments, we concluded that ORF50 has
two CBP-binding domains, the basic domain and the LXXLL
motif, and that these two domains are necessary for stable
binding to CBP in vivo.
HDAC1-interacting domain within ORF50. To determine
whether ORF50 and HDAC1 associate in vivo, we transiently
transfected plasmids expressing Flag-tagged ORF50 and HA-
tagged HDAC1 into 293T cells. Cell extracts were prepared
and immunoprecipitated with a monoclonal antibody against
the Flag epitope. Anti-Flag immunoprecipitates were sepa-
rated on SDS-PAGE and blotted with anti-HA antibody.
HDAC1 was detected in the immunoprecipitates from cells
FIG. 3. Modulation of the transcriptional activation function of ORF50 by c-Jun and E1A. (A) Luciferase activity from pFR-Luc was measured
in 293T cells that had been transiently cotransfected with Gal4/ORF50 and either E1A or c-Jun expression vectors. The luciferase activity
generated from Gal4/ORF50 activation of the reporter in the absence of the other expression vectors is normalized to 1. (B) The mammalian
two-hybrid assay was performed to test the effects of E1A and c-Jun on CBP23 activation of VP16/ORF50. The luciferase activity generated from
Gal4/CBP23 activation of the reporter in the absence of the other expression vectors is normalized to 1.
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transfected with Flag-tagged ORF50, but not from cells trans-
fected with the blank vector (Fig. 5A). We then performed the
GST pull-down assay using the various ORF50 deletion mu-
tants and GST-HDAC1 to determine the ORF50 binding do-
main of HDAC1 (Fig. 5B). ORF50 N299 and N246 did not
show binding to GST-HDAC1, while N449 and all of the larger
ORF50 mutants bound to HDAC1. With respect to the N
terminal ORF50 deletion mutants, C301-691 bound to the
HDAC, while C581-691 did not.
To characterize the ORF50-HDAC interaction in vivo, we
tested the effects of HDAC1 and TSA treatment on the ability
of the ORF50 deletion mutants to activate transcription (Table
1). 293T cells were cotransfected with Gal4-Luc reporter plas-
mid, expression plasmids encoding HDAC1 and ORF50, and
the various ORF50 deletion mutants fused to the Gal4 DNA-
binding domain. In some experiments, the cells were treated
with TSA. The ORF50 N449 fragment was responsive to
HDAC1 cotransfection and TSA treatment, but further C-
terminal ORF50 deletions abolished this responsiveness.
C301-691 was sensitive to HDAC1 and stimulated by TSA, but
further N-terminal ORF50 deletions abolished these effects.
From the above results, we conclude that the HDAC1-binding
FIG. 4. CBP-interacting domains within ORF50. (A) The domains within ORF50 and the ORF deletion mutants are shown. ORF50 contains
the basic domain, leucine zipper motif (LZ), and the transcriptional activation domain (TAD). The proline-rich domain is located between amino
acids 385 and 600. The LXXLL motif, which is conserved in SRC-1 and P/CAF, is located between amino acids 593 and 597 of ORF50. (B) The
mammalian two-hybrid assay was performed to define the CBP interaction domain of ORF50. CBP was introduced into the pM vector to generate
the Gal4 DNA-binding domain-fused CBP construct (left graph). ORF50 and its deletion mutants were introduced into the VP16 vector, and the
luciferase reporter gene was fused to Gal4 DNA-binding sites. Identical assays were performed with pM/CBP23, which contained the CBP2 and
CBP3 fragments (right graph). In each case, the luciferase activity generated by Gal4 activation of the reporter in the absence of the other
expression vectors is normalized to 1. (C) Expression of VP16 fusion proteins. 293T cells were transfected with the indicated vectors, and extracts
were analyzed by blotting with anti-VP16 antibody. (D) GST pull-down assays were performed with in vitro-translated, 35S-labeled amino- or
carboxyl-terminally deleted forms of ORF50 and GST-CBP2.
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domain in ORF50 is located between amino acids 301 and 449,
which contains several proline residues (Fig. 4A).
CBP and HDAC1 colocalize with ORF50 in vivo. We next
assessed whether ORF50, HDAC, and CBP complexes were
colocalized in 293T cells. GFP-tagged ORF50 was located
mainly in the nucleus, while GFP alone showed a diffuse pat-
tern throughout the cytoplasm and nucleus (Fig. 6A). All of
the ORF50 deletion mutants tested in this study localized to
the nucleus, and thus the difference in the transcriptional ac-
tivities of the mutants did not result from changes in their
subcellular localization (Fig. 6A). Cotransfection of HA-
tagged CBP and HA-tagged HDAC1 with GFP-ORF50
yielded a yellow color, indicative of colocalization in the nu-
cleus (Fig. 6B).
DISCUSSION
Here we showed that CBP and HDAC1 interact with KSHV
ORF50. CBP bound to the amino-terminal basic domain and
the carboxyl-terminal transactivation domain of ORF50. The
Tat transactivator from the human immunodeficiency virus
also interacts with CBP/p300 through its basic domain (17).
p160 factors such as NCoA-1/SRC-1 and other transcriptional
coactivators capable of interacting with liganded nuclear re-
ceptors have a common motif that contains a core consensus
LXXLL sequence which is also found in ORF50 (16, 24, 29,
31). SRC-1, TIF-2/GRIP-1/NcoA-2, and p/CIP contain
LXXLL motifs in a conserved central domain, which has been
identified as the nuclear receptor interaction domain. SRC-1
also has LXXLL motifs in a carboxyl-terminal domain that
interacts with the hydrophobic binding pocket of CBP/p300
(24). In this study, we showed that the LXXLL motif in the
transcriptional activation domain of ORF50 interacts with
CBP. It is the first report that the viral protein uses the LXXLL
motif as a CBP-interacting domain in addition to the cellular
proteins. It is interesting that the basic domain and the LXXLL
motifs of ORF50 interact independently with CBP and that
TABLE 1. The effects of ORF50 and HDAC1 cotransfection and TSA treatment of 293T cells on the transcriptional activation function of
ORF50 and ORF50 deletion mutantsa
Expression
plasmid
transfected
Relative luciferase activity
No addition 1TSA
1 TSA/no
addition
1
HDAC1
1 HDAC1/
no addition
Gal4 1 0.94 0.94 1.5 1.50
Gal4/ORF50 4,192 8,562 2.04 1,090 0.26
Gal4/N672 4,548 9,333 2.05 1,240 0.27
Gal4/N626 2,962 5,933 2.00 607 0.20
Gal4/N599 7.8 30 3.84 3 0.38
Gal4/N589 5.54 41.2 5.77 2.5 0.45
Gal4/N449 8.42 42 4.99 3 0.36
Gal4/N299 3.54 2.72 0.77 3.98 1.12
Gal4/N246 2.54 3.1 1.22 3.32 1.31
Gal4/C301-691 2,500 6,250 2.5 750 0.3
Gal4/C581-691 546 500 0.92 539 0.99
Gal4/C607-691 240 205 0.85 255 1.06
Gal4/LXXAA 1,240 —b — — —
a A luciferase reporter gene with Gal4 binding sites was cotransfected with a control expression plasmid (Gal4) or an expression plasmid encoding various versions
of ORF50 fused to the Gal4 DNA binding domain (10 ng). In some experiments, an expression plasmid encoding HDAC1 (1 mg) was cotransfected (1 HDAC1). Some
of the transfected cells were treated with TSA (0.1 mg/ml) (1 TSA). The luciferase activity of each ORF50 mutant was determined. Three independent experiments
were performed for each condition, and a representative result is shown for each experiment. The outcomes of all three experiments were very similar. In each case,
the activity of Gal4 in the absence of HDAC1 and TSA is normalized to a value of 1.
b —, not determined.
FIG. 5. In vivo interaction of ORF50 with HDAC1 and HDAC1-
interacting domain within ORF50. (A) Immunoprecipitation of ex-
tracts from 293T cells transfected with Flag-tagged ORF50 and HA-
tagged HDAC1. (B) The HDAC interaction domain within ORF50
was identified using GST-fused HDAC and GST pull-down assays.
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these two domains are necessary for ORF50 transcriptional
activation function.
Transcriptional repression domains have been reported to
exist in transcriptional factors. Several transcription factors
contain alanine-rich, glutamine-rich, glycine-rich, and proline-
rich sequences in their repression domains, although the pre-
cise consensus sequences and the mechanism by which these
domains repress transcription have yet to be determined (11,
34). Comparative analysis of the amino acid sequence of the
ORF50 repression domain (amino acids 301 to 449) has failed
to reveal any homology to the primary sequence motifs of the
repression domains described above. Repression of transcrip-
tion by ORF50 was mediated through interaction of the pro-
line-rich central region of ORF50 with HDAC1. Whether the
interaction of a proline-rich domain in a transcription factor
with HDAC is common mechanism of transcriptional repres-
sion by other transcription-regulatory proteins remains to be
determined.
In this study, we demonstrated that KSHV ORF50 bound to
CBP/p300 and HDAC1 and these transcriptional cofactors
modulated the transcriptional activation function of ORF50. It
is possible that the interaction of ORF50 with CBP and
HDAC1 is determined by the relative concentration of each
protein in KSHV-infected cells; however, we are not able to
test whether the interaction of ORF50 with CBP and HDAC1
is mutually exclusive. Using the results herein, we propose a
model for the regulation of ORF50 transcriptional activation.
The starting point of the lytic cycle of KSHV is the induction
of ORF50. CBP functions as a positive regulator of the ORF50
transactivator, while HDAC1 acts as a negative regulator. The
repression of ORF50 through interaction with HDAC1 could
set a threshold level for activation of the KSHV lytic cycle. If
the endogenous concentration of HDAC1 is higher than that
of CBP, depending on the status of the infected cells, the lytic
phase is slowed, and cells return to the latency phase. HDAC1
may play an important role in controlling latent and lytic cycles
of KSHV by acting as a sensor of the conditions for lytic
replication in the infected cells. KSHV could use this inhibitory
regulation by cellular proteins to replicate at the proper time,
according to cellular status. Alternatively, the repression of
ORF50 transcriptional activity by HDAC1 may function as a
defense mechanism to protect the cell from replication of the
virus.
In the present work, we focus our attention on the transcrip-
tional activity of ORF50 modulated by CBP. However, it is
possible that ORF50 could modulate the transcriptional activ-
ities of the cellular transcription factors through interaction
with CBP, as in the case of several CBP-interacting viral pro-
teins. If CBP is a limiting factor in the cells, the interaction of
ORF50 with CBP could repress the transcriptional activities of
other transcription factors through depletion of CBP. Experi-
ments designed to assess the role of ORF50 in regulation of
the cellular transcription factors are under way.
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